We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Abbott to Acquire i-STAT for $392 Million

By HospiMedica staff writers
Posted on 16 Dec 2003
In a move to further enhance the company's position in point-of-care (POC) diagnostics, Abbott Laboratories (Abbott Park, IL, USA) has agreed to acquire i-STAT Corp. More...
(East Windsor, NJ, USA) for about U.S.$392 million.

i-STAT is a leading manufacturer of POC diagnostic systems, including critical care assays for blood gases, electrolytes, general chemistries, and hematocrit. Recently the company began marketing immunoassay tests for troponin I, for emergency department testing of patients presenting with chest pain. The company's i-STAT Central Data Station is widely used in hospitals to store and organize information on tests that have been performed. Abbott and i-STAT entered into a strategic alliance for POC testing in 1998, and the two companies are currently negotiating an amendment to the existing agreement to assure an orderly transition process.

"Through our strategic alliance with i-STAT and the MediSense Precision PCx and point-of-care data management systems, Abbott has established a leading position in point-of-care diagnostics that will be further enhanced by this acquisition,” said Richard A. Gonzalez, president and COO, medical products group, Abbott Laboratories. "It provides an excellent fit with our long-term strategy of expanding our capabilities in diagnostics while targeting medical needs at the point of patient care.”






Related Links:
Abbott Labs
i-STAT

Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.